Skip to main content

Table 1 Patient characteristics

From: Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

No. of patients 11  
Gender (%)
 Male 8 (72.7)
 Female 3 (27.3)
Age (years)
 Median (range) 72 (56–84)
ECOG performance status (%)
 0 4 (36.4)
 1 6 (54.5)
 2 1 (9.1)
Smoking status (%)
 Never 4 (36.4)
 Ex/current 7 (63.6)
Asbestos inhalation history (%)
 +  6 (54.5)
 −  5 (45.5)
Histology (%)
 Epithelial type 11 (100.0)
1st line regimen
 CDDP + PEM 5 (45.5)
 CBDCA + PEM 6 (54.5)
Regimen line (%)
 2nd 10 (90.9)
 3rd 1 (9.1)
  1. CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin